Wolfson Wohl Cancer Research Centre, Institute of Cancer Sciences, University of Glasgow, Glasgow, Scotland G61 1BD, UK.
The Kinghorn Cancer Centre, Cancer Division, Garvan Institute of Medical Research, Sydney, New South Wales 2010, Australia.
Nature. 2015 Oct 15;526(7573):361-70. doi: 10.1038/nature15819.
An enhanced understanding of the molecular pathology of disease gained from genomic studies is facilitating the development of treatments that target discrete molecular subclasses of tumours. Considerable associated challenges include how to advance and implement targeted drug-development strategies. Precision medicine centres on delivering the most appropriate therapy to a patient on the basis of clinical and molecular features of their disease. The development of therapeutic agents that target molecular mechanisms is driving innovation in clinical-trial strategies. Although progress has been made, modifications to existing core paradigms in oncology drug development will be required to realize fully the promise of precision medicine.
从基因组研究中获得的对疾病分子病理学的深入了解，正在促进针对肿瘤离散分子亚类的治疗方法的发展。相关的巨大挑战包括如何推进和实施靶向药物开发策略。精准医学的核心是根据患者疾病的临床和分子特征为其提供最合适的治疗方法。针对分子机制的治疗药物的开发正在推动临床试验策略的创新。尽管已经取得了进展，但需要对肿瘤药物开发中现有的核心范例进行修改，才能充分实现精准医学的承诺。
